Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment [Globe and Mail, The (Toronto, Canada)]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Globe and Mail, The
clinical trials market surges toward a projected $25.61 billion valuation by 2035 [1] , a structural rotation is favoring 'registration-ready' platforms that demonstrate exceptional efficacy and pivotal-trial alignment with 2026's evolving FDA regulatory frameworks [2] . Investors are increasingly prioritizing late-stage and newly commercial companies poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ: ONCY), BioNTech (NASDAQ: BNTX), MAIA Biotechnology (NYSE-A: MAIA), Acrivon Therapeutics (NASDAQ: ACRV), and ImmunityBio (NASDAQ: IBRX). Read more at newswire.ca This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- $207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswire
- Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal CancerGlobeNewswire
- $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 2/4/26 - Form 8-K
- 1/20/26 - Form 4
- 1/15/26 - Form 8-K
- ONCY's page on the SEC website